Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma by Meletios A. Dimopoulos, Antonio Palumbo, Paolo Corradini, Michele Cavo, Michel Delforge, Francesco Di Raimondo, Katja C. Weisel, Albert Oriol, Markus Hansson, Angelo Vacca, María Jesús Blanchard, Hartmut Goldschmidt, Chantal Doyen, Martin Kaiser, Mario Petrini, Pekka Anttila, Anna Maria Cafro, Reinier Raymakers, Jesus San-Miguel, Felipe de Arriba, Stefan Knop, Christoph Röllig, Enrique M. Ocio, Gareth Morgan, Neil Miller, Mathew Simcock, Teresa Peluso, Jennifer Herring, Lars Sternas, Mohamed H. Zaki, and Philippe Moreau Blood Volume 128(4):497-503 July 28, 2016 ©2016 by American Society of Hematology
Investigator-assessed response to treatment using IMWG criteria. Investigator-assessed response to treatment using IMWG criteria. BORT, bortezomib; CR, complete response; LEN, lenalidomide; VGPR, very good partial response. Meletios A. Dimopoulos et al. Blood 2016;128:497-503 ©2016 by American Society of Hematology
Survival. Survival. (A) PFS. (B) OS. Meletios A. Dimopoulos et al. Blood 2016;128:497-503 ©2016 by American Society of Hematology